Screener
ARS Pharmaceuticals, Inc. SPRY Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $33.66M+114% | $22.68M+184% | $28.09M-67.6% | $32.5M+1,472% | $15.72M+3,043% | ||
| $4.7M+16.4% | $4.34M+46.9% | $3.44M+13.7% | $2.75M-37.8% | $4.04M-41.5% | ||
| $77.58M+42.8% | $72.2M+75.7% | $59.96M+68.9% | $74.75M+288% | $54.31M+507% | ||
| $95.12M+50.2% | $82.83M+83.4% | $69.55M+76.6% | $85.69M+260% | $63.33M+300% | ||
| -$61.47M-29.1% | -$60.15M-61.8% | -$41.47M— | -$53.19M-145% | -$47.61M-210% | ||
| -182.6%+120pp | -265.2%+201pp | -147.6%— | -163.7%+888pp | -302.9%+2,765pp | ||
| -$874K-132% | -$473K-115% | $61K-98.0% | $2.04M-22.1% | $2.73M-3.3% | ||
| —— | —— | -$42.84M-2,168% | -$42.84M-2,168% | -$42.84M-2,168% | ||
| —— | —— | -$20K-128% | -$20K-128% | -$20K-128% | ||
| -$62.34M-38.9% | -$60.62M-78.6% | -$41.32M-183% | -$51.15M-167% | -$44.88M-259% | ||
| -185.2%+100pp | -267.3%+158pp | -147.1%-205pp | -157.4%+768pp | -285.6%+2,218pp | ||
| -$0.63-37.0% | -$0.61-74.3% | -$0.42-182% | -$0.52-160% | -$0.46-254% | ||
| -$61.05M-29.0% | -$59.75M-61.9% | -$41.05M-2,054% | -$52.8M-143% | -$47.34M-209% | ||
| -181.4%+120pp | -263.4%+199pp | -146.1%-149pp | -162.5%+888pp | -301.2%+2,763pp | ||
| -$61.47M-29.1% | -$60.15M-61.8% | -$41.47M-2,102% | -$53.19M-145% | -$47.61M-210% |
FAQ
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $116.9M in revenue over the trailing twelve months, up 4.1% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $215.4M over the trailing twelve months, a -184.2% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.18.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
